
Moolec Science
Molecular farming producing animal proteins in plants.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 Valuation: €0.0 -138.1x EV/EBITDA | round | |
investor | €0.0 | round | |
* | $30.0m | Post IPO Convertible | |
Total Funding | 000k |
USD | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | - | 522 % |
EBITDA | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | - | (5754 %) | (117 %) |
Profit | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | (5722 %) | (130 %) |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | - | 149 % | 32 % |
Source: Company filings or news article
Related Content
Moolec Science is a science-based food ingredient company that pioneers molecular farming technology to produce animal proteins within plants. The company was co-founded in 2020 as a spin-off from Bioceres Crop Solutions by Gastón Paladini, Dr. Martín Salinas, and Dr. Henk Hoogenkamp. Paladini, the initial CEO, brought over two decades of experience from his family's major meat production business in Argentina, providing deep industry insight. In April 2025, Alejandro Antalich, a seasoned executive in biotechnology and life sciences, took over as CEO.
Moolec's core technology genetically engineers crops like soybeans, peas, and safflower to express animal proteins, creating hybrid ingredients that enhance the taste, texture, and nutritional value of food products. This approach combines the cost-effectiveness and scalability of plant-based agriculture with the functional and organoleptic properties of animal-based proteins. The business model focuses on developing and commercializing these proprietary ingredients, targeting both the alternative protein and broader processed meat markets. Rather than costly extraction processes, Moolec's strategy is to sell ingredients where animal proteins are embedded within the plant protein matrix.
The company's product pipeline includes "Piggy Sooy™," soybeans containing pork proteins, and "PEEA1," peas that produce bovine myoglobin. It has also developed GLASO™, a safflower-derived nutritional oil rich in gamma-linolenic acid (GLA), and Chymosin SPC, a bovine enzyme for cheesemaking. Moolec has achieved significant regulatory milestones, receiving clearance from the USDA for its genetically engineered safflower, soybean, and pea crops in the United States. The company went public on the Nasdaq in January 2023 via a SPAC merger. In June 2025, Moolec completed a major business combination with Bioceres Group, Nutrecon, and Gentle Tech, significantly expanding its capabilities into biological agricultural inputs, climate-resilient seeds, and precision fermentation.
Keywords: molecular farming, animal proteins, food ingredients, ag-tech, biotechnology, alternative protein, sustainable food, plant-based technology, genetic engineering, food science, soybean protein, pea protein, safflower oil, meat alternatives, dairy alternatives, crop science, food technology, NASDAQ:MLEC, Piggy Sooy, GLASO, Bioceres, precision fermentation, sustainable agriculture
Investments by Moolec Science
Edit

